![Attreyi Mukherjee](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Attreyi Mukherjee
Direktor/Vorstandsmitglied bei Impetis Biosciences Ltd.
Profil
Attreyi Mukherjee currently works as a Director at Impetis Biosciences Ltd.
Aktive Positionen von Attreyi Mukherjee
Unternehmen | Position | Beginn |
---|---|---|
Impetis Biosciences Ltd.
![]() Impetis Biosciences Ltd. BiotechnologyHealth Technology Part of Tata Chemicals Ltd., Impetis Biosciences Ltd. is an IP focused drug discovery and licensing company founded in 2017. Impetis is headquartered in Mumbai, India, and seeks to license its assets to pharma companies for further development. The Indian company has developed therapeutic assets for autoimmune and inflammatory diseases, immuno-oncology, and Nonalcoholic steatohepatitis (NASH). The company's therapeutic assets include Receptor Activator (GRA), Bruton's Tyrosine Kinase Inhibitors (BTKi), ROR?t Inhibitor Program, GPR91 antagonists, and Adenosine receptor antagonists. The Board of Directors includes Mr. KRS Jamwal (Executive Director, Tata Industries), Mr. S. Sriram (CFO and Company Secretary, Tata Industries), and Attreyi Mukherjee (Senior Corporate Counsel, Tata Industries Ltd. & Director, Impetis Biosciences). | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Impetis Biosciences Ltd.
![]() Impetis Biosciences Ltd. BiotechnologyHealth Technology Part of Tata Chemicals Ltd., Impetis Biosciences Ltd. is an IP focused drug discovery and licensing company founded in 2017. Impetis is headquartered in Mumbai, India, and seeks to license its assets to pharma companies for further development. The Indian company has developed therapeutic assets for autoimmune and inflammatory diseases, immuno-oncology, and Nonalcoholic steatohepatitis (NASH). The company's therapeutic assets include Receptor Activator (GRA), Bruton's Tyrosine Kinase Inhibitors (BTKi), ROR?t Inhibitor Program, GPR91 antagonists, and Adenosine receptor antagonists. The Board of Directors includes Mr. KRS Jamwal (Executive Director, Tata Industries), Mr. S. Sriram (CFO and Company Secretary, Tata Industries), and Attreyi Mukherjee (Senior Corporate Counsel, Tata Industries Ltd. & Director, Impetis Biosciences). | Health Technology |